قائمة المحتويات
1. Introduction and Technical Survey. - 2. Fibril Formation by Short Synthetic Peptides. – 3. In vitro Oligomerization and Fibrillogenesis of Amyloid-beta Peptides. – 4. Tau Fibrillogenesis. – 5. Prion protein Aggregation and Fibrillogenesis In vitro. – 6. α-Synuclein Aggregation and Modulating Factors. – 7. Pathological Self-aggregation of β2-microglobulin: A Challenge for Protein Biophysics. – 8. Islet amyloid polypeptide – Aggregation and fibrillogenesis in vitro and its Inhibition. – 9. Mechanisms of Transthyretin Aggregation and Toxicity. – 10. Fibrillogenesis of Huntingtin and Other Glutamine Containing Proteins. – 11. Aggregation and Fibrillogenesis of Proteins not Associated with Disease – A few Case Studies. – 12. Experimental Inhibition of Peptide Fibrillogenesis by Synthetic Peptides, Carbohydrates and Drugs. - 13. Experimental inhibition of fibrillogenesis and neurotoxicity by amyloid-beta (Aβ) and other disease-related peptides/proteins by plant extracts and herbal compounds. – 14. Alzheimer’s Disease. – 15. Modeling the Polyglutamine Aggregation Pathway in Huntington’s Disease: from Basic Studies to Clinical Applications. – 16. Parkinson’s Disease. – 17. Human Prion Diseases: From Kuru to Variant Creutzfeldt-Jakob Diseasae. – 18. Animal Prion Diseases. – 19. β2-microglobulin Amyloidosis. – 20. Systemic AA Amyloidosis. – 21. Familial Amyloidotic Polyneuropathy and Transthyretin. – 22. The Challenge of Systemic Immunoglobulin Light-chain Amyloidosis (AL).